An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cardiovascular Systems, Inc. (NASDAQ: CSII) will host a live webcast on February 3, 2022, at 8:00 a.m. CT to discuss its fiscal 2022 Q2 results for the period ending December 31, 2021. An earnings release will precede the call. The company focuses on innovative solutions for vascular and coronary disease, notably through its orbital atherectomy system, which targets calcified plaque in arteries. Further details are available on their website.
Positive
Company's focus on innovative medical device solutions for vascular disease.
Upcoming fiscal Q2 earnings call demonstrates transparency and engagement with investors.
Negative
None.
Live Webcast at 8:00 a.m. CT (9:00 a.m. ET)
ST. PAUL, Minn.--(BUSINESS WIRE)--
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2022 second-quarter conference call on Thursday, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET). CSI management will discuss results for its fiscal second quarter ended December 31, 2021, and its financial outlook. CSI will issue an earnings release prior to the call on February 3, 2022.
To access the live webcast, please register for the webcast here. A webcast replay will be available later the same day.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For additional information, please visit www.csi360.com and connect on Twitter @csi360.